Dr. Asma Jabeen
Senior Scientist, ADC Therapeutics
- Our Services
- Platforms
- Target Solutions
- Technologies
- Service Types
- Our Science
- About Us
- Contact us
Join our panel of experts as they delve into the latest advancements in preclinical models for immunotherapies, including Antibody-Drug Conjugates (ADCs), and immune-mediated cellular therapies such as CAR-T, T-cell engagers etc.
In this session, our scientists will showcase how Crown Bioscience’s clinically relevant preclinical models, including patient-derived and syngeneic platforms, are accelerating the development of novel immunotherapies. Learn how advanced in vitro, in vivo, and ex vivo models can be leveraged to optimize target selection, evaluate immune-modulating mechanisms, and de-risk clinical translation.
Whether you are exploring novel targets, testing next-generation therapies, or navigating the complex tumor microenvironment, our speakers will break it down for you in a way that is practical and actionable. At Crown Bioscience, we are passionate about supporting the immuno-oncology community with the tools, models, and expertise needed to develop treatments that make a real difference for patients.
Spaces are limited. Light lunch will be served. Reserve your seat now and be part of the conversation!
Senior Scientist, ADC Therapeutics
Director of Scientific Engagement, Crown Bioscience
Principal Scientist, Crown Bioscience
